RePORT International Resources

The Mayo Clinic Center for Tuberculosis webinar library features recorded sessions covering diagnostics, treatment, prevention, and comorbidities, aimed at expanding individuals' knowledge and skills in tuberculosis care.

This monthly webinar series offers healthcare professionals the latest insights in tuberculosis (TB). Tuberculosis experts will discuss screening, diagnosis, and treatment of TB disease and latent TB infection (LTBI). Topics include considerations for pediatric and adult populations, clinical updates, diagnostic methods, and treatment strategies. Healthcare professionals managing patients with TB can stay informed on research developments and emerging treatment regimens for active TB and LTBI, exploring innovative approaches to enhance patient adherence and outcomes.

This webinar explores mycobacterial diagnostic tools and their applications in TB prevention and treatment. Learn to effectively use and interpret Tuberculin Skin Tests (TSTs), interferon-gamma release assays (IGRAs), and cultures for diagnosing latent TB infection (LTBI) and active TB disease. Case studies will highlight real-world challenges and best practices for leveraging these tools in clinical practice.

Tuberculosis (TB) in pregnancy poses serious risks to both mother and fetus if not promptly diagnosed and managed. This webinar covers key aspects of TB diagnosis, treatment, and complications during pregnancy. Participants will also be introduced to the TB Pregnancy Toolkit and other resources to support effective care for pregnant patients.

McGill TBcentre - many webinars and mini courses (all prerecorded)

TSTin4D and IGRAin4D are both are decision aids providing information about the likelihood of developing TB disease, dying from TB, as well as post-TB disability, in the next 20 years in a person with a positive tuberculin skin test or a positive Interferon gamma release assay and a known risk factor. This also provides information on the potential benefits and risks of TB preventive therapy. Also added is information for the person considering whether to accept TB preventive therapy, including a handout that includes predictions for them, and some basic information about TB prevention.

This Notice of Funding Opportunity (NOFO) invites eligible academic or research institutions to apply for funding support to purchase latest scientific equipment that will enhance and modernize research-supporting operations of existing shared biomedical research facilities. Targeted are laboratory research core facilities, animal research facilities, and other similar shared-use research spaces. The goal of this NOFO is to strengthen research-auxiliary activities of biomedical research facilities and to enhance the efficiency of their operations. The NOFO does not support the purchase of scientific research instruments or their components, nor components of building-level infrastructure equipment that indirectly support research activities.

This course requires about 40 total hours to complete. It is self-paced, has open enrollment, and can be accessed for 60 days.

Applications for the third round of the New York State Biodefense Commercialization Fund are now closed. Please check back for updates on the program. The $40 million Biodefense Commercialization Fund was created to encourage and accelerate the development and commercialization of solutions for serious infectious disease threats, including COVID-19 and its variants, while fostering the creation of new life science businesses and supporting industry growth. The Fund has offered grants to startup companies and academic institutions that are developing promising diagnostics, vaccines, therapeutics, and such other innovations as epidemiological surveillance tools, environmental controls, and clinical care advances that address or mitigate infectious disease threats. For the current application period, New York State seeks applications focusing on the specific areas of interest: - Novel platforms for development of rapid Point-of-Care (POC) diagnostics (examples include, but are not limited to, CRISPR and/or Isothermal-based platforms) with priority given to POC diagnostics that can perform as well as or better than existing lab tests. - Processes that integrate easy-to-use sample preparation and allow for access in low resourced settings. - Novel tools for sequencing and serology-based tests that support infectious disease and pathogen surveillance

The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges. A major objective of the program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This Notice of Funding Opportunity (NOFO) invites SBIR grant applications from SBCs to support later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and which will require eventual Federal regulatory approval/clearance. The purpose of this NOFO and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. Projects proposed under this NOFO MUST be relevant to the NHLBI mission (see B. Scientific/Technical Scope). This NOFO is specifically intended to benefit clinical practice by accelerating the commercialization of novel products that require ultimate approval/clearance by a Federal regulatory agency. This NOFO will give competitive preference and funding priority to applications deemed likely to result in a clinically-relevant commercial product as indicated by the applicant’s ability to secure independent third-party investor funds that equal or exceed the requested NHLBI funds, and competitive preference and funding priority to applications that show a strong potential for clinically relevant commercial products, as evidenced by the applicant’s ability to secure independent third-party investor funds equal to or exceeding the total requested costs. Please refer to the website for detail announcement and key dates.

The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Version 2.1 used in … clinical trials for safety data reporting to maintain accuracy and consistency in the evaluations of SAEs.

This document provides a detailed list of essential documents” (regulatory documents). “The purpose and/or description of these documents is/are given with a recommended location where they should be filed during the conduct of a clinical trial.

NIH NIAID - Grants and Fundings - Searchable Database

Advancing TB research through open-access, multi-domain, global TB data and tools.

The NIH Extramural Nexus is the NIH's official platform for updates on grants policies, application processes, and funding news. Hosted within the NIH Grants & Funding website, it serves as a centralized resource for researchers, administrators, and institutions navigating the NIH extramural research landscape. The platform offers timely information on policy changes, application tips, and new resources, ensuring the research community stays informed and compliant with NIH requirements.

Learn the basics with NIH Grants Process: A Walk-Through for Beginners Tune in for answers to your questions in the NIH Expert Q&A Panel: Part 1 Test your knowledge with Submission Policies: You Make the Call More questions and answers in the NIH Expert Q&A Panel: Part 2 Take our panelists’ advice: Grant Application Tips from NIH Experts

Most important training for any investigator would be HSP/GCP where they need to learn and understand how Ethical conduct of research is done and why it is important. I have pasted various links below that cover all the topics extensively. DAIDS learning portal, HANC network , DAIDS score manual have good training modules .

This document provides a detailed list of source documentation requirements during the conduct of a clinical trial. Source documentation refers to the record of the participant before, during and after a trial.

The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote the dissemination and implementation of evidence-based interventions among relevant communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed in the notice. Application DEADLINE: Multiple dates, see announcement.

This online course is presented by Dr. David M. Murray, the NIH Associate Director for Prevention and Director of Office of Disease Prevention. This course, updated in September 2024, is meant to help researchers design trials involving groups or clusters.